A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck

Objectives: To summarize existing evidence about whether the presence of mutant or upregulated p53 is a prognostic factor for patients presenting with squamous cell carcinoma arising from the larynx, oropharynx, hypopharynx, or oral cavity. Method: Relevant articles were identified using strict criteria for systematic searches. Associations between mutant or upregulated p53 versus wild-type or low/undetectable p53 in relation to overall survival and DFS were summarized by extracting or deriving hazard ratio (HR) estimates. Random-effects meta-analyses were used to account for between-study heterogeneity and to summarize the effect of p53 across studies. Results: The meta-analyses gave a statistically significant pooled HR for overall survival in oral cavity [pooled HR, 1.48; 95% confidence interval, (95% CI), 1.03-2.11], and for disease-free survival in oral cavity (pooled HR, 1.47; 95% CI, 1.12-1.93) and in oropharynx (pooled HR, 0.45; 95% CI, 0.27-0.73). Despite attempts to limit it, between-study heterogeneity was large in the majority of meta-analyses and the prognostic value of p53 was generally inconsistent and inconclusive across studies. Conclusion: The meta-analysis results highlight that current evidence about the prognostic value of p53 in patients with squamous cell carcinaoma of the head and neck is inconclusive. Large heterogeneity exists across studies in study-level and patient-level characteristics, making it difficult to ascertain a clear picture. Future studies are required in which p53 expression is investigated in a more standardized and biologically informative manner. In particular, prospectively planned individual patient data meta-analyses are needed to establish the prognostic importance of p53 for specific subgroups of patients undergoing specific treatments. Cancer Epidemiol Biomarkers Prev; 19(2); 574–87

[1]  G. Ogden,et al.  p53 over-expression in laryngeal carcinoma is not predictive of response to radiotherapy. , 1997, Oral oncology.

[2]  H. Saya,et al.  Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx , 2000, International journal of cancer.

[3]  K. Sasaki,et al.  The significance of PCNA and p53 protein in some oral tumors. , 1995, International journal of oral and maxillofacial surgery.

[4]  Y. Furuta,et al.  Correlation of clinicopathological parameters and biological markers related to apoptosis and proliferative activity with a clinical outcome in squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy. , 2001, Auris, nasus, larynx.

[5]  M. Daidone,et al.  Biological markers as indicators of pathological response to primary chemotherapy in oral‐cavity cancers , 1998, International journal of cancer.

[6]  David Moher,et al.  Addressing Reporting Biases , 2008 .

[7]  X. Wang,et al.  Overexpression of p53 nuclear protein in premalignant and malignant laryngeal lesions , 1999, European Archives of Oto-Rhino-Laryngology.

[8]  L. Sellmann,et al.  Prognostic Significance of p53/bcl‐2 Co‐expression in Patients With Laryngeal Squamous Cell Carcinoma , 2000, The Laryngoscope.

[9]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[10]  A. Rosman,et al.  Prognostic implications of normal (<0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome. , 2008, The American journal of cardiology.

[11]  J. Jacobs,et al.  Prognostic significance of p53 and FHIT in advanced oropharyngeal carcinoma. , 2004, American journal of otolaryngology.

[12]  Richard D Riley,et al.  Primer: an evidence-based approach to prognostic markers , 2005, Nature Clinical Practice Oncology.

[13]  J. Fenton,et al.  The history, aetiology and epidemiology of laryngeal carcinoma. , 2001, Clinical otolaryngology and allied sciences.

[14]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[15]  C. Cordon-Cardo,et al.  Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[17]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[18]  H. Pai,et al.  Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. , 1998, International journal of radiation oncology, biology, physics.

[19]  C. Hwang,et al.  The clinicopathological significance of p53 and p21 expression in squamous cell carcinoma of hypopharyngeal cancer. , 2003, Cancer letters.

[20]  E. Campo,et al.  p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors , 1995, The Journal of pathology.

[21]  T. Helliwell,et al.  p53 protein expression in tumours from head and neck subsites, larynx and hypopharynx, and differences in relationship to survival. , 1998, Clinical otolaryngology and allied sciences.

[22]  H. Eckel,et al.  Ki‐67 (MIB1), p53, and Lewis‐X (LeuM1) as Prognostic Factors of Recurrence in T1 and T2 Laryngeal Carcinoma , 2000, The Laryngoscope.

[23]  P C Lambert,et al.  Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future , 2003, British Journal of Cancer.

[24]  Orsolya Csuka,et al.  Progression of head and neck squamous cell cancer , 2005, Cancer and Metastasis Reviews.

[25]  E. Speel,et al.  Marked differences in survival rate between smokers and nonsmokers with HPV 16‐associated tonsillar carcinomas , 2008, International journal of cancer.

[26]  R. Taylor 'Mouseyes': an aid to wound measurement using a computer. , 1997, Journal of Wound Care.

[27]  M. Nakamizo,et al.  Clinical role of p53 and p21WAF1/CIP1 in squamous cell carcinoma of the pyriform sinus. , 1998, Acta oto-laryngologica.

[28]  K. Jung,et al.  Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). , 2007, Oral oncology.

[29]  M. Takahara,et al.  Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients’ prognosis , 2007, Acta oto-laryngologica.

[30]  V. Kosma,et al.  p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Vojtesek,et al.  Discriminating functional and non‐functional p53 in human tumours by p53 and MDM2 immunohistochemistry , 2005, The Journal of pathology.

[32]  G. Pruneri,et al.  p63 in Laryngeal Squamous Cell Carcinoma: Evidence for a Role of TA-p63 Down-Regulation in Tumorigenesis and Lack of Prognostic Implications of p63 Immunoreactivity , 2002, Laboratory Investigation.

[33]  H. Buyukbayram,et al.  Prognostic Value of PCNA and Mutant p53 Expression in Laryngeal Squamous Cell Carcinoma , 2004, Cancer investigation.

[34]  A. Mizuno,et al.  p53, mdm2, and p21 expression in oral squamous cell carcinomas: relationship with clinicopathologic factors. , 2002, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[35]  N. Malats,et al.  P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.

[36]  Michele Tarsilla Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[37]  J. Schiller,et al.  Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes , 1992, Journal of virology.

[38]  N. Konishi,et al.  p53 tumor suppressor gene and ras oncogene mutations in hypopharyngeal squamous cell carcinomas. , 1997, International journal of oncology.

[39]  W. Sauerbrei,et al.  Identification of clinically useful cancer prognostic factors: what are we missing? , 2005, Journal of the National Cancer Institute.

[40]  K. Yoneda,et al.  Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. , 1998, Pathology, research and practice.

[41]  T. Ebert,et al.  p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer , 2000, European Urology.

[42]  T. Soussi p53 alterations in human cancer: more questions than answers , 2007, Oncogene.

[43]  L. Kowalski,et al.  Clinicopathological and immunohistochemical evaluation of oral squamous cell carcinoma in patients with early local recurrence. , 2007, Oral oncology.

[44]  T. Abraham,et al.  Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma , 2005, Modern Pathology.

[45]  R. Lewensohn,et al.  Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma--relation to radiotherapy response and survival. , 2001, Anticancer research.

[46]  A. Carvalho,et al.  Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database , 2005, International journal of cancer.

[47]  J. Wilson,et al.  Expression of cyclin-dependent kinase inhibitor p21(WAF1) and p53 tumour suppressor gene in laryngeal cancer. , 2000, Clinical otolaryngology and allied sciences.

[48]  Qifeng Yang,et al.  Prognostic significance of vascular endothelial growth factor protein levels in T1‐2 N0 laryngeal cancer treated with primary radiation therapy , 2007, Cancer.

[49]  A. Robson,et al.  Effective Head and Neck Cancer Management, Third Consensus Document 2002 , 2002 .

[50]  N. Jović,et al.  p53 mutations and human papillomavirus infection in oral squamous cell carcinomas: correlation with overall survival. , 2005, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[51]  Harald zur Hausen,et al.  Papillomaviruses in the causation of human cancers - a brief historical account. , 2009, Virology.

[52]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[53]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[54]  J. Lunec,et al.  P53 overexpression in head and neck carcinoma and radiotherapy results. , 1996, International Journal of Radiation Oncology, Biology, Physics.

[55]  S. Fisher,et al.  P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. , 2000, International journal of radiation oncology, biology, physics.

[56]  J. Hornung,et al.  Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[57]  A. Hanlon,et al.  P53 Alteration in Oral Tongue Cancer is Not Significantly Associated with Age at Diagnosis or Tobacco Exposure , 2005, Tumori.

[58]  David J Spiegelhalter,et al.  A re-evaluation of random-effects meta-analysis , 2009, Journal of the Royal Statistical Society. Series A,.

[59]  K. Vousden Outcomes of p53 activation - spoilt for choice , 2006, Journal of Cell Science.

[60]  John P A Ioannidis,et al.  Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.

[61]  W. Dinjens,et al.  A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8 , 2003, International journal of cancer.

[62]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[63]  Jill Hayden,et al.  Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.

[64]  D. Caldarelli,et al.  Prognostic significance of Bcl‐2 and p53 expression in advanced laryngeal squamous cell carcinoma , 2001, Head & neck.

[65]  A. Russo,et al.  TP53 mutations and S‐phase fraction but not DNA‐ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma , 2006, Journal of cellular physiology.

[66]  S. Furukawa,et al.  An analysis of the prognostic significance of p53 status for squamous cell carcinoma of the oral cavity treated by radiotherapy. , 1998, Oral oncology.

[67]  J. L. Frank,et al.  p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx , 1994, Cancer.

[68]  John P A Ioannidis,et al.  Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.

[69]  C. Tsien,et al.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Riera,et al.  Detection of p53 protein in oropharyngeal carcinoma. Prognostic implications. , 1996, Archives of otolaryngology--head & neck surgery.

[71]  M. Boyd,et al.  p53: a molecular marker for the detection of cancer. , 2008, Expert opinion on medical diagnostics.

[72]  D G Altman,et al.  Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond , 2009, British Journal of Cancer.

[73]  F. Bosch,et al.  Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control , 2002, Oncogene.

[74]  H. Saito,et al.  Expression of protein p27 is associated with progression and prognosis in laryngeal cancer , 1999, The Laryngoscope.

[75]  F. Sarkar,et al.  Prognostic significance of p53 gene mutations in laryngeal cancer , 1999, The Laryngoscope.

[76]  R. Rezola,et al.  p53 and Cyclin D1 as Prognostic Factors in Squamous Cell Carcinoma of the Larynx , 2003, The Laryngoscope.